Marcaine (Bupivacaine Hydrochloride, Anhydrous)

Marcaine (bupivacaine hydrochloride) is used in the local anesthetic class for regional nerve block and pain control.

• Regional anesthesia for surgical procedures: provides prolonged sensory and motor block during operations.
• Epidural analgesia: delivers continuous pain relief during labor, postoperative period, or chronic pain management.
• Infiltration anesthesia: allows localized numbness for minor surgical or diagnostic procedures.

• Bupivacaine hydrochloride produces reversible inhibition of voltage‑gated sodium channels on neuronal membranes, stabilizing the inactive state of the channel. This prevents depolarization and blocks the initiation and propagation of nerve impulses, resulting in loss of sensation in the targeted area. The effect is concentration‑dependent and lasts several hours due to high protein binding. Its high affinity for cardiac and skeletal muscle sodium channels also contributes to its potency but requires careful monitoring.

Bupivacaine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Injection site pain: discomfort, tenderness, or bruising at the site of epidural or infiltration injection.
• Numbness or tingling: transient sensory loss or paresthesia in the area supplied by the block.
• Lightheadedness: mild dizziness or feeling of faintness occurring shortly after administration.
• Nausea: occasional gastrointestinal upset, sometimes accompanied by vomiting.

Serious or Rare Side Effects

• Cardiovascular toxicity: arrhythmias, severe hypotension, bradycardia, or cardiac arrest requiring emergency intervention.
• Central nervous system toxicity: seizures, tremors, visual disturbances, or loss of consciousness.
• Allergic reactions: rash, itching, swelling, bronchospasm, or anaphylactic shock.
• Methemoglobinemia: rare blood disorder causing cyanosis and reduced oxygen delivery.

When using Marcaine, clinicians should observe specific precautions to minimize risks and ensure optimal outcomes.

• Patient assessment: evaluate cardiovascular and neurological status before administration.
• Dose limitation: adhere to recommended maximum doses and avoid accidental intravascular injection.
• Monitoring: continuously monitor heart rate, blood pressure, and level of consciousness during and after the block.
• Drug interactions: review concomitant medications that may potentiate toxicity, especially other local anesthetics or sodium channel blockers.
• Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited.
• Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Bupivacaine can interact with several agents, affecting its safety profile.

Major Interactions (Avoid)

• Other local anesthetics: combined use may increase risk of systemic toxicity.
• Class I antiarrhythmic drugs (e.g., quinidine, procainamide): can potentiate cardiac conduction disturbances.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise plasma concentrations of bupivacaine.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask signs of hypotension.
• Diuretics: can alter plasma protein binding, affecting free drug levels.
• Opioids administered concurrently: may enhance central nervous system depression.